Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710345 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy
A Phase 2 study, sponsored by Talphera.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
NCT01710345 is a Phase 2 study that has completed, run by Talphera. The registered enrollment target is 101 participants.
The verdict
NCT01710345, a Phase 2 study, has completed, sponsored by Talphera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
Study Summary
This is a dose-finding study to determine if the sublingual administration of the Sufentanil NanoTab is safe and effective in the treatment of post-operative pain.
Interventions
- DRUG Placebo NanoTab
- DRUG Sufentanil NanoTab 20 mcg
- DRUG Sufentanil NanoTab 30 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710345
The ClinicalTrials.gov registry entry for NCT01710345 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Talphera, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo NanoTab is the first listed.
NCT01710345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710345 about?
NCT01710345 is a clinical study titled "Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy". This is a dose-finding study to determine if the sublingual administration of the Sufentanil NanoTab is safe and effective in the treatment of post-operative pain.
What is the current status of trial NCT01710345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2012-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01710345?
The interventions under investigation include: Placebo NanoTab (DRUG), Sufentanil NanoTab 20 mcg (DRUG), Sufentanil NanoTab 30 mcg (DRUG).
Who is sponsoring clinical trial NCT01710345?
This trial is sponsored by Talphera, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.